•国家自然科学基金 青年项目
时间：2019年01月至 2021年 12月
编号：81802738
名称：DCLK1与K-Ras/MAPKs通路相互作用推动胰腺癌发生发展的机制研究
经费：21.00万元
•北京市自然科学基金 面上项目
时间：2020年01月至 2022年 12月
编号：7202051
名称：DCLK1抑制抗肿瘤免疫推动结直肠肿瘤发生的机制研究
经费：20.00万元
•北京市青年骨干个人项目
时间：2017年01月至 2018年 12月
编号：2016000021469G195
名称：DCLK1 及相关分子标志物的表达水平与结肠癌诊断及预后相关性的研究
经费：4.00万
•北京市属医院科研培育计划项目
时间：2017年01月至 2019年 12月
编号：pX2017017
名称：DCLK1及相关miRNA 表达与结肠癌诊断和预后相关性研究
经费：15.00万
主要研究领域的论文/著作：
1、Yan R, Fan X, Xiao Z, Liu H, Huang X, Liu J, Zhang S, Yao J, An G, Ge Y. Inhibition of DCLK1 sensitizes resistant lung adenocarcinomas to EGFR-TKI through suppression of Wnt/β-Catenin activity and cancer stemness. Cancer Lett 2022 04 10;531.(IF 8.7)
2、Ge Y, Liu H, Zhang Y, Liu J, Yan R, Xiao Z, Fan X, Huang X, An G.Inhibition of DCLK1 kinase reverses epithelial-mesenchymal transition and restores T-cell activity in pancreatic ductal adenocarcinoma. Transl Oncol 2022 Jan 05;17. (IF 4.2)
3、Ge Y, Fan X, Huang X, Weygant N, Xiao Z, Yan R, Liu H, Liu J, An G, Yao J. DCLK1-Short Splice Variant Promotes Esophageal Squamous Cell Carcinoma Progression Via the MAPK/ERK/MMP2 Pathway. Mol Cancer Res 2021 12;19(12). (IF 5.8)
4、Yao J, Duan L, Huang X, Liu J, Fan X, Xiao Z, Yan R, Liu H, An G, Hu B, Ge Y. Development and Validation of a Prognostic Gene Signature Correlated With M2 Macrophage Infiltration in Esophageal Squamous Cell Carcinoma.Front Oncol 2021;11 (IF 6.2)
5、Zheng H, Liu H, Ge Y, Wang X. Integrated single-cell and bulk RNA sequencing analysis identifies a cancer associated fibroblast-related signature for predicting prognosis and therapeutic responses in colorectal cancer. Cancer Cell Int 2021 Oct 20;21(1) (IF 5.7)
6、Ge Y, Zhang H, Weygant N, Yao J. Differential Dermatologic Adverse Events Associated With Checkpoint Inhibitor Monotherapy and Combination Therapy: A Meta-Analysis of Randomized Control Trials. Front Pharmacol 2021;12. (IF 5.8)
7、 Tao L, Zhang H, An G, Lan H, Xu Y, Ge Y, Yao J. Balancing the Risk-Benefit Ratio of Immune Checkpoint Inhibitor and Anti-VEGF Combination Therapy in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Front Oncol 2021;11 (IF 6.2)
8、Rui Yan, JianJian Li, Ying Zhou, Li Yao, Ruya Sun, Ying Xu, Yang Ge, Guangyu An, Inhibition of DCLK1 down-regulates PD-L1 expression through Hippo pathway in human pancreatic cancer. Life Sci. 241 (2020), 117150. (IF 3.5)
9、Yang Ge, C. Benedikt Westphalen, Wen Wee Ma, Kenneth J. Vega, Nathaniel Weygant. Implications for Tumor Microenvironment and Epithelial Crosstalk in the Management of Gastrointestinal Cancers. Journal of Oncology. (2019), 4835318. (IF 2.6)
10、Heshu Liu, TaoWen, Ying Zhou, Xiaona Fan, Tan Du, Tianbo Gao, Lina Li, Jian Liu, Lei Yang, Jiannan Yao, Yang Ge, Guangyu An. DCLK1 Plays a Metastatic-Promoting Role in Human Breast Cancer Cells. Biomed Res Int. (2019), 1061979. (IF 2.2)
11、Yang Ge, Yi-Kun Kang, Li Dong, Li-Hong Liu, Guangyu An. The efficacy of dietary Spirulina as an adjunct to chemotherapy to improve immune function and reduce myelosuppression in patients with malignant tumors. Transl Cancer Res. 2019,8(4):1065-1073. (IF 1.1)
12、Ge Y, Weygant N, Qu D, May R, Berry WL, Yao J, Chandrakesan P, Zheng W Zhao L, Zhao KL, Drake M, Vega KJ,Bronze MS, Tomasek JJ, An G, Houchen CW. Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer. Int J Cancer. 2018,143:1162-1175. (IF 7.4)
13、Weygant N, Ge Y, Qu D, Kaddis JS, Berry WL, May R, Chandrakesan P, Bannerman-Menson E, Vega KJ, Tomasek JJ, Bronze MS, An G, Houchen CW. Survival of patients with gastrointestinal cancers can be predicted by a surrogate microRNA signature for cancer stem-like cells marked by DCLK1 kinase. Cancer Res. 2016 Jul 15;76(14):4090-9. (IF 9.1)
14、Ge Y, Yan D, Deng H, Chen W, An G. Novel Molecular Regulators of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)-Induced Apoptosis in NSCLC Cells. Clinical Lab. 2015;61(12):1855-63. (IF 1.0)
Tao Gu, Yang Ge, Yuezhang Song, Zhanzhao Fu, Yunjie Zhang, Guangxia，Wang, Shasha Shao & Tao WenHepatic radiofrequency ablation causes an increase of circulating histones in patients with hepatocellular carcinoma. Scand J Clin Lab Invest. 2015;75(7):621-627. (IF 1.4)
既往承担的临床试验：
1、作为主要研究者所承担的临床试验：2项；受试者数：20人
如：
①重组人源化抗PD-1单克隆抗体（HX008）联合化疗对比帕博利珠单抗联合化疗作为一线方案治疗晚期或转移性非鳞非小细胞肺癌的II/III期临床研究（HX008-NSCLC-Ⅱ、Ⅲ）
②生姜泻心汤防治肺癌化疗相关腹泻的多中心、随机、对照临床研究 （北京市科委）
2、作为协作研究者所承担的临床试验：10项；受试者数：60人
如：
PD-1抗体SHR-1210联合培美曲塞加卡铂一线治疗晚期或转移性非鳞状非小细胞肺癌患者的开放性、随机、多中心III期临床研究
中华医学会 委员